Media.Player

Novel Gut Microbiome-based Diagnostic and Therapeutic for Neonates at Risk of Childhood Atopy and Asthma

Technology Benefits

Asthma currently affects more than 300 million people worldwide and is the most prevalent childhood disease in western countries. 1 in 12 children in the US aged 0-17 suffer from Asthma. Poorly controlled and undiagnosed asthma in small children can result in trips to the emergency room, hospital stays, missed workdays for parents and suffering that can quickly turn life-threatening. Childhood asthma is currently predicted using the modified asthma predictive index (mAPI), which, using risk factors from the first three years of life, predicts asthma in school aged children. This invention leverages observations that risk of childhood atopy and asthma is characterized by specific changes in functional genes and products of the neonatal gut microbiome, to devise a diagnostic test that effectively identifies children at high risk of atopy and asthma as early as one-month of age.  This technology provides the following advantages:  Ability to identify children at risk for developing atopy and asthma as early as one-month of age. This would provide the invaluable opportunity for early intervention to prevent disease development.  Non-invasive and easy to perform in children, as it utilizes fecal samples for analysis.  Uses well-established, inexpensive and trusted assays, like LC-MS and qPCR for sample analysis.

Detailed Technology Description

Researchers at University of California, San Francisco have developed a diagnostic test that uses measurements of the copy numbers of three bacterial genes and the level of a bacterial metabolite, in conjunction with known early-life risk factors to identify children at high-risk for developing atopy and asthma and developed targeted treatment. This data is used to calculate an asthma/atopy prediction score, which effectively quantifies the risk of developing these diseases by age two for atopy, and age four for asthma.

Others

Stage of Development

Preclinical

Looking for Partners

To develop and commercialize this technology as a clinical diagnostic test for early detection of atopy and asthma risk, in early infancy and targeted treatment.

Data Availability

Under NDA/CDA

Tech ID/UC Case

29339/2018-087-0

Related Cases

2018-087-0, 2018-198-0

*Abstract

UCSF researchers have developed a novel gut microbiome-based diagnostic test and targeted treatment for early-life identification of atopy or asthma risk in children.

*Principal Investigator

Name: Sophia Levan

Department:

Name: Susan Lynch

Department:

Country/Region

USA